Inhibikase Secures $50 Million Financing To Advance PAH Program

Inhibikase Therapeutics secured $50 million in gross financing to advance its PAH program, and its shares rose after the announcement. The company sold 25 million shares of common stock to RA Capital Management through an at-the-market (ATM) facility, pushing the stock up 5% in the immediate reaction. Inhibikase said the new capital, combined with existing reserves, is expected to fund operations through the topline data readout in Part B of its ongoing global Phase 3 IMPROVE-PAH study, subject to the full exercise of outstanding Series A and B warrants. The financing was conducted under a shelf registration statement that became effective in June 2025, with a prospectus supplement filed in December 2025. Lead asset IKT-001 is a prodrug of imatinib mesylate for pulmonary arterial hypertension, a disease affecting about 50,000 Americans. The pivotal Phase 3 trial enrolls patients across roughly 180 sites worldwide. The stock closed Tuesday at $2.06 and was $2.04 in after-hours trading.